Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

한국어

ILSUNG IS CO., LTD.

일성아이에스003120KOSPISector: Pharma & Biotech
₩20,5500.24%Market cap ₩273.3BAs of Sep 2, 2026 close · updated once daily
Market cap
₩273.3B
#399 in KOSPI
235.0x
Sector median 16.3x (profitable cos.)
0.71x
Sector median 1.61x
0.0%
Sector median 0.0%
B
Grade B60.9 ptsTop 31% of 2,523 graded stocksMethodology v2.0

As of Sep 2, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCurrentCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band B with a total score of 60.9 points.

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩18,300High ₩28,300
Latest close
Price change by period
1W
1.20%
1M
2.20%
3M
7.60%
1Y
16.80%

As of the Sep 2, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

73.9/100
How much debt does it carry relative to equity?
4.3%
Sector median 51.6%
Sector lowhighTop 3% in sector
Can it cover what's due within a year?
1746.9%
Sector median 191.7%
Sector lowhighTop 6.7% in sector
How much of revenue becomes profit?
-9.6%
Sector median -2.4%
Sector lowhighBottom 46.5% in sector
How much did it earn on its own capital?
0.3%
Sector median -4.5%
Sector lowhighTop 41.1% in sector

Source filing: annual report (separate) — view original

2

Growth momentum

34.2/100
How much did revenue grow in a year?
-6.8%
Sector median 6.4%
Sector lowhighBottom 22.5% in sector
Has it grown steadily over three years?
1.6%
Sector median 4.9%
Sector lowhighBottom 36% in sector
Did core profits grow in a year?
35.3%
Sector median 3.6%
Sector lowhighTop 26.4% in sector
Are core profits higher than three years ago?
-574.9%
Sector median 3.5%
Sector lowhighBottom 4.6% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (separate) — view original

3

Price attractiveness

68.6/100
Is the price expensive relative to earnings?
235.0x
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 39.5% in sector
Is the price expensive relative to book value?
0.71x
Sector median 1.61x
Sector lowhighTop 23.3% in sector

Valuation uses the Sep 2, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Total cash dividends (FY2025)
₩8.6B

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (separate) — view original

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 4 met · 4 not met · 1 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩1.2B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩3.9B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
3.1% → 0.3%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
₩3.9B vs ₩1.2B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
3.0% → 4.1%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
2607.3% → 1746.9%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not computable

Not computed — share count data is unavailable

Operating margin up
Whether operating income over revenue rose from the prior year.
Met
-13.8% → -9.6%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.165x → 0.162x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original

Grade change history

Jul 23, 2026B

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Corporate value-up plan filed

Filed a “기업가치제고계획(자율공시)” (corporate value-up plan, voluntary disclosure) (filed 2026-03-27). View filing

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source
Periodic report filedMay 15, 2026Source

View in the filings calendar →